Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619339 · ClinicalTrials.gov registry record · Phase 1
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07619339: Recruiting Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07619339 is a Phase 1 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07619339, a Phase 1 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.
Interventions
- DRUG Ivonescimab
- DRUG Tepotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-05-27 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07619339
The ClinicalTrials.gov registry entry for NCT07619339 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ivonescimab is the first listed.
NCT07619339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07619339 about?
NCT07619339 is a clinical study titled "A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer". The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combin...
What is the current status of trial NCT07619339?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-05-27. Estimated completion is 2029-05.
What interventions are being tested in trial NCT07619339?
The interventions under investigation include: Ivonescimab (DRUG), Tepotinib (DRUG).
Who is sponsoring clinical trial NCT07619339?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.